Somatostatin is named as an intervention in 2 current clinical trials in our China register. 1 is recruiting patients now. All registered phases are Not applicable. The sponsor with the most trials is Tongji Hospital (1). The most-studied condition is Rectal Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Rectal Cancer Undergoing Ultra-Low Anterior Resection
NCT07605611 · ClinicalTrials.gov ↗ · Rectal Cancer, Anastomotic Leakage
|
Not applicable | Recruiting | Tongji Hospital | China |
|
Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Variceal Bleeding and Renal Dysfunction
NCT07252401 · ClinicalTrials.gov ↗ · Liver Cirrhosis
|
Not applicable | Not yet open | General Hospital of Shenyang Military Region | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
| Lead sponsor | Trials |
|---|---|
| Tongji Hospital | 1 |
| General Hospital of Shenyang Military Region | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name Somatostatin as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Tongji Hospital (1) and General Hospital of Shenyang Military Region (1). The number in brackets is how many trials each organisation leads.
The registers we track list 2 entries for Somatostatin: 2 German notices. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Somatostatin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Somatostatin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Somatostatin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.